Insider · CIK 0001706847

Velleca Mark A.

Reports to the SEC for 2 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001706847

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-21	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, PRESIDENT & CEO	AAward	+600K sh	—	—	600,000
2025-01-30	BDTXBlack Diamond Therapeutics, Inc.A Award	Director, PRESIDENT & CEO	AAward	+75K sh	—	—	121,522
2025-01-30	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, PRESIDENT & CEO	AAward	+500K sh	—	—	500,000
2024-02-14	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, PRESIDENT & CEO	AAward	+537K sh	—	—	537,000
2023-09-17	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, PRESIDENT & CEO	AAward	+1M sh	—	—	1,000,000
2023-09-15	BDTXBlack Diamond Therapeutics, Inc.A Award	Director, PRESIDENT & CEO	AAward	+5,208 sh	$3.60	+$18.7K	46,522
2023-08-08	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+57.3K sh	$0.39	+$22.3K	173,286
2023-08-08	G1 Therapeutics, Inc.S Sale	Director	SSale	−57.3K sh	$2.00	−$114K	116,000
2023-08-08	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,714 sh	$0.30	+$814.2	118,714
2023-08-08	G1 Therapeutics, Inc.S Sale	Director	SSale	−2,714 sh	$2.02	−$5,482.28	116,000
2023-08-08	G1 Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−57.3K sh	—	—	0
2023-08-08	G1 Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,714 sh	—	—	242,286
2023-06-16	BDTXBlack Diamond Therapeutics, Inc.A Award	Director, PRESIDENT & CEO	AAward	+8,929 sh	$2.10	+$18.8K	41,314
2023-05-16	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, PRESIDENT & CEO	AAward	+16.5K sh	—	—	16,500
2023-03-16	BDTXBlack Diamond Therapeutics, Inc.A Award	Director, PRESIDENT & CEO	AAward	+11.2K sh	$1.67	+$18.8K	32,385
2022-12-16	BDTXBlack Diamond Therapeutics, Inc.A Award	Director, PRESIDENT & CEO	AAward	+8,424 sh	$1.50	+$12.6K	21,157
2022-10-18	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+15K sh	$0.39	+$5,850	131,000
2022-10-18	G1 Therapeutics, Inc.S Sale	Director	SSale	−15K sh	$11.70	−$175K	116,000
2022-10-18	G1 Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−15K sh	—	—	57,286
2022-09-20	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+20K sh	$0.39	+$7,800	136,000
2022-09-20	G1 Therapeutics, Inc.S Sale	Director	SSale	−20K sh	$13.50	−$270K	116,000
2022-09-20	G1 Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−20K sh	—	—	72,286
2022-09-16	BDTXBlack Diamond Therapeutics, Inc.A Award	Director, PRESIDENT & CEO	AAward	+4,294 sh	$2.62	+$11.3K	12,733
2022-08-16	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+80K sh	$0.39	+$31.2K	196,000
2022-08-16	G1 Therapeutics, Inc.S Sale	Director	SSale	−80K sh	$12.64	−$1.01M	116,000
2022-08-16	G1 Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−80K sh	—	—	92,286
2022-06-17	BDTXBlack Diamond Therapeutics, Inc.A Award	Director, PRESIDENT & CEO	AAward	+5,542 sh	$2.03	+$11.3K	8,439
2022-06-10	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, PRESIDENT & CEO	AAward	+15K sh	—	—	15,000
2022-03-18	BDTXBlack Diamond Therapeutics, Inc.A Award	Director, PRESIDENT & CEO	AAward	+2,897 sh	$3.02	+$8,748.94	2,897
2022-02-07	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+15K sh	$0.39	+$5,850	116,000
2022-02-07	G1 Therapeutics, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−15K sh	—	—	172,286
2021-11-09	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+40K sh	$0.39	+$15.6K	101,000
2021-11-09	G1 Therapeutics, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−40K sh	—	—	187,286
2021-08-09	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, PRESIDENT & CEO	AAward	+30K sh	—	—	30,000
2021-07-15	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$0.39	+$3,900	71,000
2021-07-15	G1 Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$18.49	−$185K	61,000
2021-07-15	G1 Therapeutics, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	227,286
2021-07-14	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$0.39	+$3,900	71,000
2021-07-14	G1 Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$19.08	−$191K	61,000
2021-07-14	G1 Therapeutics, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	237,286
2021-07-13	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$0.39	+$3,900	71,000
2021-07-13	G1 Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$19.45	−$195K	61,000
2021-07-13	G1 Therapeutics, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	247,286
2021-06-17	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$0.39	+$3,900	71,000
2021-06-17	G1 Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$21.77	−$218K	61,000
2021-06-17	G1 Therapeutics, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	257,286
2021-06-16	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$0.39	+$3,900	71,000
2021-06-16	G1 Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$21.74	−$217K	61,000
2021-06-16	G1 Therapeutics, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	267,286
2021-06-15	G1 Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$0.39	+$3,900	71,000

Recent filings

Accepted (ET)
Jan 234
Velleca Mark A.0001706847-26-000002
SEC(opens sec.gov)
Jan 314
Velleca Mark A.0001415889-25-002494
SEC(opens sec.gov)
Feb 154
Velleca Mark A.0001415889-24-003963
SEC(opens sec.gov)
Sep 184
Velleca Mark A.0001415889-23-013339
SEC(opens sec.gov)
Aug 104
Velleca Mark A.0001562180-23-006271
SEC(opens sec.gov)
Jun 164
Velleca Mark A.0001415889-23-009959
SEC(opens sec.gov)
May 174
Velleca Mark A.0001415889-23-008246
SEC(opens sec.gov)
Mar 204
Velleca Mark A.0001415889-23-005218
SEC(opens sec.gov)
Dec 194
Velleca Mark A.0001415889-22-012797
SEC(opens sec.gov)
Oct 204
Velleca Mark A.0001562180-22-007293
SEC(opens sec.gov)
Sep 224
Velleca Mark A.0001562180-22-006791
SEC(opens sec.gov)

Companies

Address

C/O BLACK DIAMOND THERAPEUTICS, INC. 245 FIRST STREET, 18TH FLOOR

CAMBRIDGE, MA, 02142